Abstract
Relevance. At the children's oncological hospital guidelines to treat patients with several groups of antibiotics at the same time, which ensures the formation of multi-resistant strains of Clostridium difficile, which have a selective advantage for the Clostridium difficile infection developing, and also cause epidemics and /or in associating with an increase in the severity of Clostridium difficile – infection. Aims. Multidrug resistance Clostridium difficile strains and Clostridium difficile infection rate at pediatric oncological hospital. Results. An investigation of the Clostridium difficile resistance strains carried out among children at the children's oncological hospital. 143 toxigenic strains are resistant to moxifloxacin 72.41%, clindamycin 63.72%, rifampicin 35.54%, tetracycline 26.45%, tigecycline 11.42%, vancomycin 4.4%, metronidazole 3.9%. At the same time, the increase multidrug-resistant strains proportion note at the level of 3–4% per year. However, the rate of Clostridium difficile infection among children at the oncological hospital remained at the level of 0.4% to 3.1% with a downward trend. As a result, statistical calculations showed the absence of correlation between multidrug resistance and morbidity. Conclusions. Detection of multidrug-resistant microorganisms among toxigenic Clostridium difficile strains proves the need for further study of this problem in Russia and the advisability of monitoring Clostridium difficile infection rate and multidrug resistance Clostridium difficile strains at pediatric oncological hospitals.
Highlights
Assessment of the Effect of Multidrug Resistance Clostridium difficile Clinical Strains on the Dynamics of Clostridium difficile Infection Rate at Pediatric Oncological Hospital MG Shvydkaya**1, AM Zatevalov1, DT Dzhandarova2, SD Mitrokhin3, OE Orlova3 1 G
At the children's oncological hospital guidelines to treat patients with several groups of antibiotics at the same time, which ensures the formation of multi-resistant strains of Clostridium difficile, which have a selective advantage for the Clostridium difficile infection developing, and cause epidemics and / or in associating with an increase in the severity of Clostridium difficile – infection
An investigation of the Clostridium difficile resistance strains carried out among children at the children's oncological hospital. 143 toxigenic strains are resistant to moxifloxacin 72.41%, clindamycin 63.72%, rifampicin 35.54%, tetracycline 26.45%, tigecycline 11.42%, vancomycin 4.4%, metronidazole 3.9%
Summary
Определить тенденцию антибиотикорезистентности токсигенных клинических штаммов C. difficile и динамику заболеваемости Clostridium difficile инфекцией в детском онкологическом стационаре. Среди детей в детском онкологическом стационаре проведено исследование резистентности штаммов Clostridium difficile. Полирезистентность токсигенных клинических штаммов Clostridium difficile в детском онкологическом стационаре. Multidrug resistance Clostridium difficile strains and Clostridium difficile infection rate at pediatric oncological hospital. For citation: Shvydkaya MG, Zatevalov AM, Dzhandarova DT, et al Assessment of the Effect of Multidrug Resistance Clostridium difficile Clinical Strains on the Dynamics of Clostridium difficile Infection Rate at Pediatric Oncological Hospital. Антибиотикорезистентность C. difficile к клиндамицину, эритромицину, моксифлоксацину, рифампицину, тетрациклину, тигециклину в первую очередь имеет значение для эпидемиологического наблюдения как у пациентов с клиническими проявлениями клостридиальной инфекции, так и у бессимптомных носителей. Цель настоящего исследования – определить тенденцию антибиотикорезистентности токсигенных клинических штаммов C. difficile и проследить динамику заболеваемости Clostridium difficile инфекцией в детском онкологическом стационаре. C. difficile strains proportion with antibiotic resistance in the feces of pediatric oncological hospital patients treated in 2013–2015
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.